CAR T Cell Therapy Toxicities: Mastering Recognition and Response

1. Recall the pathophysiologic mechanism for the development of chimeric antigen receptor (CAR) T cell related toxicity.
2. Compare toxicities amongst CAR T cell products.
3. Select the appropriate treatment for a patient according to the grade of cytokine release syndrome (CRS).
4. Produce a plan for the management of a patient experiencing immune-effector cell associated neurotoxicity syndrome (ICANS).
5. Identify clinical and laboratory manifestations of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS).
6. Recognize movement and neurocognitive treatment-emergent adverse events (MNTs) with ciltacabtagene autoleucel.

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation

The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this enduring material will award 1.50 Nursing Contact Hour(s) which includes APRN 1.50 Pharmacotherapeutics credit(s).

The University of Texas MD Anderson Cancer Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until October 13, 2027. PAs should only claim credit commensurate with the extent of their participation.

The University of Texas MD Anderson Cancer Center designates this knowledge-based activity for 1.50 hours under UAN JA0004118-0000-24-008-H06-P and UNA JA0004118-0000-24-008-H06-T. Credits will be provided to NABP CPE Monitor within 60 days after the activity completion. Learners must provide their NABP e-profile ID and Date of Birth in their MyCE Profile for credits to be reported to CPE Monitor. 

American Board of Internal Medicine

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pediatrics

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.50 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Robyn Davis, MPH
Sr Conference Coordinator
The University of Texas MD Anderson Cancer Center

Activity Administrator

Nothing to disclose

Asha Demla, DNP
Associate Director, Nursing Programs
The University of Texas MD Anderson Cancer Center

CE Reviewer

Nothing to disclose

Elizabeth J. Shpall, MD
Chair Ad Interim, Stem Cell Transplantation
The University of Texas MD Anderson Cancer Center

Course Director

Nothing to disclose

Anne Rain T Brown, PharmD, PharmD, BCCCP, FCCM
MD Anderson Cancer Center

Faculty

Nothing to disclose

Bryan Do, PharmD
Takeda Oncology

Faculty

Nothing to disclose

Alexandra Lovell, PharmD
MD Anderson Cancer Center

Faculty

Nothing to disclose

Sherry Adkins, MSN
Advanced Practice Supervisor, Lymphoma Research
MD Anderson. Cancer Center

Planning Committee Member

Nothing to disclose

Kelley Fliehler, Other
MD Anderson

Planning Committee Member

Nothing to disclose

Alison M Gulbis, PharmD, BCOP, FASTCT
Dir, Clinical Pharmacy Svcs
The University of Texas MD Anderson Cancer Center

Planning Committee Member

Nothing to disclose

Sandra B Horowitz, PharmD
UT MD Anderson Cancer Center

Planning Committee Member

Nothing to disclose